- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06542874
Um estudo de pesquisa comparando quão bem diferentes doses do medicamento NNC0487-0111 reduzem o açúcar no sangue em pessoas com diabetes tipo 2
Segurança e eficácia de NNC0487-0111 subcutâneo e oral uma vez por dia uma vez por semana em participantes com diabetes tipo 2 - um estudo para determinação de dose
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Elsterwerda, Alemanha, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda, Alemanha, 04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen, Alemanha, 45136
- InnoDiab Forschung GmbH
-
Hamburg, Alemanha, 22607
- Wendisch/Dahl Hamburg
-
Hamburg, Alemanha, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, Alemanha, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Alemanha, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Kyustendil, Bulgária, 2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil, Bulgária, 2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv, Bulgária, 4002
- DCC Sveti Georgi EOOD
-
Plovdiv, Bulgária, 4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv, Bulgária, 4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv, Bulgária, 4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia, Bulgária, 1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia, Bulgária, 1431
- UMHAT "Aleksandrovska"
-
Sofia, Bulgária, 1000
- Medical centre Regina Life Clinic EOOD
-
Sofia, Bulgária, 1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia, Bulgária, 1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna, Bulgária, 9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
-
Karlovac, Croácia, 47000
- Opca bolnica Karlovac
-
Krapinske Toplice, Croácia, 49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice, Croácia, 49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek, Croácia, 31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek, Croácia, 31 000
- Klinicki bolnicki centar Osijek
-
Varaždin, Croácia, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin, Croácia, 42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Croácia, 10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, Croácia, 51 000
- KBC Rijeka, Endokrinologija
-
Rijeka, Primorje-Gorski Kotar County, Croácia, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
Poprad, Eslováquia, 05801
- DENTAVIA s.r.o.
-
Prešov, Eslováquia, 080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota, Eslováquia, 979 01
- OLIVER - MED s.r.o.
-
Žilina, Eslováquia, 010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy, Slovak Republic, Eslováquia, 93601
- Peter Farkas MD, s.r.o.
-
-
-
-
-
A Coruña, Espanha, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, Espanha, 08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta, Espanha, 41950
- Hospital Vithas Sevilla
-
Madrid, Espanha, 28007
- Hospital Gregorio Marañón
-
Pontevedra, Espanha
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander, Espanha, 39008
- Hospital Universitario Marqués de Valdecilla
-
Seville, Espanha, 41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville, Espanha, 41010
- Hospital Infanta Luisa
-
Seville, Espanha, 41950
- Hospital Nisa Sevilla Aljarafe
-
Seville, Espanha, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Estados Unidos, 90057
- Velocity Clin Research LA
-
Santa Ana, California, Estados Unidos, 92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury, Connecticut, Estados Unidos, 06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island, Florida, Estados Unidos, 32003
- Fleming Island Ctr for Clin Res
-
Hollywood, Florida, Estados Unidos, 33024
- Encore Medical Research LLC
-
Miramar, Florida, Estados Unidos, 33027
- South Broward Research LLC
-
Orlando, Florida, Estados Unidos, 32825
- Florida Inst For Clin Res
-
Orlando, Florida, Estados Unidos, 32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka, Kansas, Estados Unidos, 66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah, Kentucky, Estados Unidos, 42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville, Maryland, Estados Unidos, 20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill, Maryland, Estados Unidos, 20745
- MD Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Brigham & Women's Hospital
-
Methuen, Massachusetts, Estados Unidos, 01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy, Michigan, Estados Unidos, 48098
- Arcturus Healthcare, PLC
-
Troy, Michigan, Estados Unidos, 48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield, Missouri, Estados Unidos, 63005
- Clinical Research Professionals
-
City of Saint Peters, Missouri, Estados Unidos, 63303
- StudyMetrix Research LLC
-
-
New York
-
Albany, New York, Estados Unidos, 12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City, North Carolina, Estados Unidos, 28557
- Centricity Rsrch MHCity Multi
-
Statesville, North Carolina, Estados Unidos, 28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58104
- Lillestol Research LLC
-
Fargo, North Dakota, Estados Unidos, 58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman, Oklahoma, Estados Unidos, 73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh, Pennsylvania, Estados Unidos, 15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57702
- Health Concepts
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos, 37660
- Holston Medical Group
-
Nashville, Tennessee, Estados Unidos, 37203
- Clinical Research Associates
-
Nashville, Tennessee, Estados Unidos, 37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75230
- Velocity Clinical Res-Dallas
-
Houston, Texas, Estados Unidos, 77024
- Victorium Clinical Research
-
Houston, Texas, Estados Unidos, 77079
- PlanIt Research, PLLC
-
Houston, Texas, Estados Unidos, 77061
- Synergy Groups Medical
-
Lampasas, Texas, Estados Unidos, 76550
- Radiance Clinical Research
-
McKinney, Texas, Estados Unidos, 75069
- Tekton Research
-
Waco, Texas, Estados Unidos, 76708
- Hillcrest Family Health Center
-
-
-
-
-
Athens, Grécia, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, Grécia, 12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens, Grécia, 11527
- "Laiko" General Hospital of Athens
-
Thessaloniki, Grécia, GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grécia, GR-57001
- "Thermi" Private Hosital
-
Thessaloniki, Grécia, 564 29
- 424 Military General Training Hospital
-
Thessaloniki, Grécia, 57001
- "Thermi" Private Hosital
-
Thessaloniki, Grécia, 54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grécia, 564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Budapest, Hungria, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, Hungria, 1134
- MH Egészségügyi Központ
-
Debrecen, Hungria, 4031
- Debreceni Egyetem
-
Debrecen, Hungria, H-4031
- Debreceni Egyetem
-
Debrecen, Hungria, H-4032
- Debreceni Egyetem
-
Gyula, Hungria, 5700
- Békés Megyei Központi Kórház
-
Kaposvár, Hungria, 7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár, Hungria, H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hungria, 4032
- Debreceni Egyetem
-
-
-
-
-
Aichi, Japão, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba, Japão, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba, Japão, 261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba, Japão, 260-0804
- Akaicho Clinic
-
Ibaraki, Japão, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japão, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo, Japão, 103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo, Japão, 104-0031
- Fukuwa Clinic
-
Tokyo, Japão, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japão, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japão, 880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki, Miyazaki, Japão, 880-0034
- Heiwadai Hospital
-
-
-
-
-
Bialystok, Polônia, 15-375
- Specderm Poznańska Spółka Jawna
-
Lublin, Polônia, 20-718
- EKAMED sp. z o.o.
-
Ruda Śląska, Polônia, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw, Polônia, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska, Gornoslaskie, Polônia, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polônia, 31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim, Lesser Poland Voivodeship, Polônia, 32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica, Lower Silesian Voivodeship, Polônia, 59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica, Lower Silesian Voivodeship, Polônia, 59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polônia, 20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polônia, 08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polônia, 15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok, Podlaskie Voivodeship, Polônia, 15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polônia, 90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Brasov, Romênia, 500101
- Mariodiab Clinic SRL
-
Timișoara, Romênia, 300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara, Romênia, 300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea, Bihor County, Romênia, 410025
- SC Grand Med SRL
-
Oradea, Bihor County, Romênia, 410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest, Bucharest, Romênia, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest, Bucurestii, Romênia, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, Romênia, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş, Mureș County, Romênia, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, Romênia, 100018
- Novus Medical Clinica SRL
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Comparador de Placebo: Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in HbA1c
Prazo: From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Relative change in body weight
Prazo: From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Prazo: From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
Prazo: From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Prazo: From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
Prazo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
Prazo: At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
Prazo: From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publicações e links úteis
Publicações Gerais
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NN9490-7678
- U1111-1296-9708 (Outro identificador: World Health Organization (WHO))
- 2023-509412-28 (Outro identificador: European Medical Agency (EMA))
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .